Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP Study: Lanadelumab for HAE Prophylaxis
NCT02586805Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Started Mar 2016; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02586805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586805.